[{"id":"60bbdfcc-c05d-4873-8c66-614ba38bb554","acronym":"TAILORx","url":"https://clinicaltrials.gov/study/NCT00310180","created_at":"2021-01-18T01:04:07.094Z","updated_at":"2025-02-25T16:43:29.841Z","phase":"Phase 3","brief_title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","source_id_and_acronym":"NCT00310180 - TAILORx","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10273","initiation":"Initiation: 04/07/2006","start_date":" 04/07/2006","primary_txt":" Primary completion: 03/02/2018","primary_completion_date":" 03/02/2018","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-02-06"},{"id":"9663b458-bf8e-4744-aded-694ba1c51e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06348134","created_at":"2024-04-04T16:39:16.597Z","updated_at":"2025-02-25T13:56:14.439Z","phase":"Phase 2","brief_title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","source_id_and_acronym":"NCT06348134","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 07/01/2034","primary_completion_date":" 07/01/2034","study_txt":" Completion: 07/01/2036","study_completion_date":" 07/01/2036","last_update_posted":"2025-02-05"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"4eabc33c-7694-415e-ba33-0280ee409656","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129216","created_at":"2021-01-18T20:10:21.050Z","updated_at":"2024-07-02T16:35:05.639Z","phase":"Phase 2","brief_title":"The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer","source_id_and_acronym":"NCT04129216","lead_sponsor":"Johns Hopkins University","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/20/2019","start_date":" 02/20/2019","primary_txt":" Primary completion: 11/10/2022","primary_completion_date":" 11/10/2022","study_txt":" Completion: 11/10/2022","study_completion_date":" 11/10/2022","last_update_posted":"2024-05-07"},{"id":"e264a041-42a7-43c6-8cea-b309a736c283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101564","created_at":"2021-11-01T11:52:59.476Z","updated_at":"2024-07-02T16:35:06.853Z","phase":"Phase 2","brief_title":"Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT05101564","lead_sponsor":"Stanford University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • Truseltiq (infigratinib) • letrozole • zotatifin (eFT226) • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-30"},{"id":"535f285e-41bf-472a-ac17-cca49b4c0883","acronym":"","url":"https://clinicaltrials.gov/study/NCT05150652","created_at":"2021-12-09T18:00:11.490Z","updated_at":"2024-07-02T16:35:21.691Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer","source_id_and_acronym":"NCT05150652","lead_sponsor":"Veronica Morgan Jones","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2036","study_completion_date":" 10/01/2036","last_update_posted":"2024-01-30"},{"id":"6e6b0160-cdc4-4b39-8c92-7f7d239fef91","acronym":"PRO30178","url":"https://clinicaltrials.gov/study/NCT03219476","created_at":"2021-01-18T15:53:02.691Z","updated_at":"2024-07-02T16:35:41.730Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","source_id_and_acronym":"NCT03219476 - PRO30178","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/05/2017","start_date":" 02/05/2017","primary_txt":" Primary completion: 02/04/2020","primary_completion_date":" 02/04/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-07-27"},{"id":"3bb45c0b-82f2-4050-8899-8d4a9efd15c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993159","created_at":"2021-01-18T14:43:26.101Z","updated_at":"2024-07-02T16:36:37.043Z","phase":"Phase 2b","brief_title":"Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast","source_id_and_acronym":"NCT02993159","lead_sponsor":"Northwestern University","biomarkers":" ER • IGF1 • CD68","pipe":" | ","alterations":" ER positive","tags":["ER • IGF1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e afimoxifene • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 07/15/2022","primary_completion_date":" 07/15/2022","study_txt":" Completion: 07/15/2023","study_completion_date":" 07/15/2023","last_update_posted":"2020-12-21"},{"id":"fc5910da-ab73-4042-880e-df20fbdbf62c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238703","created_at":"2021-01-18T16:00:14.581Z","updated_at":"2024-07-02T16:37:04.362Z","phase":"Phase 4","brief_title":"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer","source_id_and_acronym":"NCT03238703","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • toremifene • Soltamox (tamoxifen citrate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 03/14/2023","primary_completion_date":" 03/14/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2018-12-27"}]